Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants

BACKGROUND: Neutralizing antibodies are approved drugs to treat coronavirus disease-2019 (COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants may reduce the antibody neutralizing activity. New monoclonal antibodies (mAbs) and antibody remolding st...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lili, Gao, Meiling, Jiao, Peng, Zu, Shulong, Deng, Yong-qiang, Wan, Dingyi, Cao, Yang, Duan, Jing, Aliyari, Saba R, Li, Jie, Shi, Yueyue, Rao, Zihe, Qin, Cheng-feng, Guo, Yu, Cheng, Genhong, Yang, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113379/
https://www.ncbi.nlm.nih.gov/pubmed/35581593
http://dx.doi.org/10.1186/s13578-022-00794-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113379/
https://www.ncbi.nlm.nih.gov/pubmed/35581593
http://dx.doi.org/10.1186/s13578-022-00794-7

Ejemplares similares